Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Belite Bio, Inc

< Previous 1 2 Next >
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Present at the JonesHealthcare Seaside Summit
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces $25 Million Registered Direct Offering
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the BTIG Ophthalmology Day
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.